About
About Shanghai Kaibao Pharmaceutical CO.,Ltd
Shanghai Kaibao Pharmaceutical CO.,Ltd engages in the research, development, production, and sale of modern traditional Chinese medicines primarily in China. The company offers heat-clearing and detoxifying products, such as Tanreqing Injection for wind-heat in the lungs with phlegm-heat obstructing the lungs, early-stage pneumonia, acute bronchitis, acute exacerbations of chronic bronchitis, and respiratory infections; and Phlegm-Heat Clearing Capsules to clear heat, resolve phlegm, and detoxifying. It also provides liver-protecting products, including Thiopronine for injection and Thiopronine enteric-coated tablets. In addition, the company provides Astragalus and Ginseng Capsules for the treatment of cardiovascular and cerebrovascular diseases. Further, it offers diclofenac sodium enteric-coated tablets; artificial bezoar metronidazole capsules; Mai'an granules; Loquat cough granules that clears the lungs, relieves cough, and reduces phlegm; compound danshen tablets; Tongmai granules to promote blood circulation and unblocks meridians; pediatric pharyngeal granules; stroke rejuvenation pills; and Xiao Chai Hu granules which relieves exterior syndromes, clears heat, soothes the liver, and harmonizes the stomach. Further, the company provides Alopecia areata; Bear bile drops that clears heat, calms the liver, and improves eyesight, as well as used for infantile convulsions and sore throat; and Shanhaidan capsules. Shanghai Kaibao Pharmaceutical CO.,Ltd was founded in 2000 and is based in Shanghai, China.
Visit company website
5 years, 5 months ago
Shanghai Kaibao Pharmaceutical CO.,Ltd is currently in a long term uptrend where the price is trading 8.7% above its 200 day moving average.
From a valuation standpoint, the stock is 55.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.3.
Shanghai Kaibao Pharmaceutical CO.,Ltd's total revenue sank by 37.5% to $172M since the same quarter in the previous year.
Its net income has dropped by 47.9% to $29M since the same quarter in the previous year.
Finally, its free cash flow grew by 106.8% to $94M since the same quarter in the previous year.
Based on the above factors, Shanghai Kaibao Pharmaceutical CO.,Ltd gets an overall score of 3/5.